Edition:
United States

Lexicon Pharmaceuticals Inc (LXRX.OQ)

LXRX.OQ on NASDAQ Stock Exchange Global Select Market

13.07USD
4:00pm EDT
Change (% chg)

$-0.62 (-4.53%)
Prev Close
$13.69
Open
$13.72
Day's High
$13.72
Day's Low
$13.06
Volume
176,296
Avg. Vol
218,304
52-wk High
$17.96
52-wk Low
$7.68

Chart for

About

Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of... (more)

Overall

Beta: 0.48
Market Cap(Mil.): $1,425.56
Shares Outstanding(Mil.): 105.83
Dividend: --
Yield (%): --

Financials

  LXRX.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -1.33 -- --
ROI: -51.40 -5.30 13.11
ROE: -174.42 -6.83 15.11

BRIEF-Lexicon Pharmaceuticals Reports Q1 Loss Per Share $0.40

* LEXICON PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

May 03 2018

BRIEF-‍Lexicon announces EMA acceptance of MAA for Sotagliflozin to treat adults with Type 1 Diabetes​

* ‍LEXICON PHARMACEUTICALS ANNOUNCES EMA ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION (MAA) FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES​ Source text for Eikon: Further company coverage:

Mar 29 2018

BRIEF-Lexicon Announces Regulatory Submissions For Sotagliflozin To Treat Adults With Type 1 Diabetes

* LEXICON PHARMACEUTICALS ANNOUNCES REGULATORY SUBMISSIONS FOR SOTAGLIFLOZIN TO TREAT ADULTS WITH TYPE 1 DIABETES

Mar 26 2018

BRIEF-Lexicon Pharmaceuticals Q4 Loss Per Share $0.27

* LEXICON PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

Feb 22 2018

Competitors

Earnings vs. Estimates